Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Immune checkpoint blockade shows promise in cancer treatment.
• Targeting the indoleamine 2,3-dioxygenase (IDO) pathway is an alternative strategy to enhance anti-tumor immunity.
• IDO-1 inhibitors have shown mixed results in clinical trials, necessitating identification of responsive patient subsets.

Purpose of the Study:

• To investigate the genomic and immunologic factors associated with IDO pathway gene expression across various cancer types.
• To identify specific cancer subtypes that may benefit from IDO-1 inhibitor therapy.

Main Methods:

• Utilized the Cancer Genome Atlas (TCGA) dataset for comprehensive analysis.
• Examined correlations between IDO-1, IDO-2, and TDO-2 gene expression and immune cell infiltration (CD8+ T-cells), tumor mutation burden, and viral (EBV, HPV, HCV, ERV3-2) expression.

Main Results:

• IDO pathway gene expression correlated with CD8+ T-cell infiltration, high mutation burden, and viral infections (EBV, HPV, HCV, ERV3-2) in most cancer types.
• Specific associations were found for IDO-1, IDO-2, and TDO-2 across different cancers.
• High mutation burden in ER+ HER2- breast cancer and ERV3-2 expression in specific breast, colon, and endometrial cancer subtypes were linked to overexpression of all three IDO pathway genes.

Conclusions:

• Genomic and immunologic features, including viral infections and mutation burden, are associated with IDO pathway gene expression.
• These findings can guide the selection of patient populations for future clinical trials involving IDO-1 inhibitors.
• Personalized treatment strategies targeting the IDO pathway may improve therapeutic efficacy in specific cancer subsets.